Publicação: Bis(diphenylphosphino)amines-containing ruthenium cymene complexes as potential anti-Mycobacterium tuberculosis agents
Carregando...
Arquivos
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Elsevier B.V.
Tipo
Artigo
Direito de acesso
Acesso aberto
Resumo
Several ruthenium complexes have been investigated regarding anti-Mycobacterium tuberculosis (anti-MTb) activity, with some diphosphine-containing ruthenium complexes comparable to first and second line drugs. However, to the best of our knowledge, there is no P-N-P-containing ruthenium complexes applied as metallodrugs. Thus, this study focused on the synthesis, characterization and anti-MTb activity of a new series of coordination compounds with general formula [RuCl(eta(6)-p-cymene)(P-N-R-P)]X (R = CH2Py (Py = pyridine) - [1a], CH2Ph (Ph = phenyl) - [1b], Ph - [1c] and p-tol (p-tol = p-tolyl) - [1d]; X = PF6- or BF4-). The complexes were fully characterized by NMR (H-1, P-31{H-1}), vibrational spectroscopy (FTIR), ESI-MS, molar conductance, elemental analysis and X-ray diffraction studies. The molecular structures of [1a]center dot PF6, [1c]center dot BF4 and [1d]center dot PF6 were determined and confirm the spectroscopic and ESI-MS data. The complexes were used in anti-MTb trials, and the preliminary results are presented. The complexes are promising anti-MTb agents with MIC90 (Minimum Inhibitory Concentration of compounds required to inhibit the growth of 90% of MTb) values comparable with the Ethambutol, the reference drug used in this work, and complex [1a]center dot BF4 presented the highest selectivity index.
Descrição
Palavras-chave
Idioma
Inglês
Como citar
Journal Of Inorganic Biochemistry. New York: Elsevier Science Inc, v. 173, p. 134-140, 2017.
